Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.

A A Adjei1

  • 1Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. adjei.alex@mayo.edu

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|December 6, 2000
PubMed
Summary

Pemetrexed disodium (ALIMTA) is a novel antifolate drug showing broad antitumor activity in various solid tumors. Clinical studies review its pharmacology, toxicity, and efficacy, including combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.

ESMO open·2025
Same author

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

ESMO open·2024
Same author

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

ESMO open·2023
Same author

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.

ESMO open·2021
Same author

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.

ESMO open·2021

Area of Science:

  • Pharmacology and Oncology
  • Anticancer Drug Development

Background:

  • Pemetrexed disodium (ALIMTA) is a novel multitargeted antifolate agent.
  • It inhibits key enzymes in folate metabolism and DNA synthesis: thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.

Purpose of the Study:

  • To review the clinical pharmacology, toxicity, and clinical activity of Pemetrexed disodium (MTA).
  • To summarize its efficacy in various solid tumors and combination therapies.

Main Methods:

  • Review of phase II and III clinical trial data.
  • Analysis of Pemetrexed disodium's (MTA) pharmacological profile.
  • Evaluation of toxicity and clinical activity across multiple tumor types.

Main Results:

Related Experiment Videos

  • Pemetrexed disodium (MTA) demonstrated broad antitumor activity in phase II trials.
  • Significant activity observed in non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas.
  • Promising results when combined with gemcitabine and cisplatin in various tumors.

Conclusions:

  • Pemetrexed disodium (ALIMTA) is a promising agent for solid tumors.
  • Ongoing phase III studies will further define its role in cancer treatment.
  • Combination therapies with MTA show potential for enhanced efficacy.